An international, randomized, double-blind, placebo-controlled, Phase III clinical trial led by scientists at Massachusetts General Hospital (MGH) demonstrated that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy extended the survival of men with metastatic, hormone-sensitive prostate cancer.